News
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Juno Therapeutics (NASDAQ: JUNO), a clinical-stage adoptive cell therapy company, saw its shares rise by 7% last month, according to data from S&P Global Market Intelligence.The biotech's....
Here's Why Juno Therapeutics Stock May Still Be Worth Buying
Juno Therapeutics (NASDAQ: JUNO), a clinical-stage adoptive cell therapy company, saw its shares rise by 7% last month, according to data from S&P Global Market Intelligence.The biotech's....
3 Blockbuster Drugs That Still Cost More Than They Should
Asking, "Is there a generic for that?" usually saves a bundle when your doctor prescribes an expensive brand-name drug. If you're one of the thousands of Americans who rely on Humira, Enbrel, or....
3 Blockbuster Drugs That Still Cost More Than They Should
Asking, "Is there a generic for that?" usually saves a bundle when your doctor prescribes an expensive brand-name drug. If you're one of the thousands of Americans who rely on Humira, Enbrel, or....
Better Buy: Celgene Corporation vs. Bristol-Myers Squibb
By most metrics, Celgene Corporation (NASDAQ: CELG) is smaller than Bristol-Myers Squibb (NYSE: BMY). Celgene has fewer employees, lower revenue, and lower earnings than BMS does. In one key way,....
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
Gilead Sciences' (NASDAQ: GILD) sliding hepatitis C revenue has taken a toll on its share price since 2015 and new competition from AbbVie (NYSE: ABBV) poses an even bigger risk to its future....
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
Gilead Sciences' (NASDAQ: GILD) sliding hepatitis C revenue has taken a toll on its share price since 2015 and new competition from AbbVie (NYSE: ABBV) poses an even bigger risk to its future....
This Dirt-Cheap Biotech Stock Is a Bargain to Buy
Gilead Sciences' (NASDAQ: GILD) sliding hepatitis C revenue has taken a toll on its share price since 2015 and new competition from AbbVie (NYSE: ABBV) poses an even bigger risk to its future....
What's Behind Celldex Therapeutics, Inc.'s 16% Rally in September?
Shares of Celldex Therapeutics, Inc. (NASDAQ: CLDX), a clinical-stage biotech, rose 16.3% in September, according to data from S&P Global Market Intelligence. It looks like investors....
Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
Have you ever had one of those days where everything seems to fall into place for you? AbbVie (NYSE: ABBV) is having one of those kinds of years. The big biotech's stock is up more than 40% so far....
Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now?
Have you ever had one of those days where everything seems to fall into place for you? AbbVie (NYSE: ABBV) is having one of those kinds of years. The big biotech's stock is up more than 40% so far....
Where Will Cara Therapeutics Be in 5 Years?
Cara Therapeutics (NASDAQ: CARA) has been one of the most exciting biotech stocks to watch in 2017, and the excitement has stemmed from both positive and negative developments. By late June, the....
Should You Sell Celgene Stock Following an Analyst Downgrade?
Celgene Corp.'s (NASDAQ: CELG) is arguably one of the globe's most successful biotech companies, yet analysts at investment researcher Morgan Stanley cut their rating on the company from equal....
Why EXACT Sciences Corporation Jumped 13.2% in September
Shares of EXACT Sciences (NASDAQ: EXAS), a diagnostics company focused on colon cancer, rose more than 13% in September, according to data from S&P Global Market Intelligence. While it was a....
Why Cerus Corporation Stock Marched Higher Today
Shares of the biomedical company Cerus Corporation (NASDAQ: CERS) rose by as much as 14.5% today on more than triple the average volume. The company's shares took flight on the news that the U.S.....
Why ImmunoGen, Inc. Dropped Today
Shares of ImmunoGen (NASDAQ: IMGN) are down 11% at 3:29 p.m. EDT after announcing yesterday that it plans to sell 13 million shares through a secondary offering. Investors could be further diluted....
Big Day on Deck for Flexion Therapeutics
Flexion Therapeutics (NASDAQ: FLXN) is about to find out if its research efforts will pay off. The U.S. Food and Drug Administration is expected to issue a go/no-go decision on its treatment for....
BOIRON : Formulaire de déclaration mensuelle des droits de vote au 30 septembre 2017
Le 5 octobre 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
Shares of Exelixis (NASDAQ: EXEL), a biotech company focused on the development of therapies to treat cancer, plunged 17% during the month of September, according to data from S&P Global....
The 2 Surprising Reasons Exelixis, Inc. Lost 17% in September
Shares of Exelixis (NASDAQ: EXEL), a biotech company focused on the development of therapies to treat cancer, plunged 17% during the month of September, according to data from S&P Global....
3 Big Pharma Stocks Set to Succeed
That disclaimer that the Securities and Exchange Commission requires mutual funds to provide to investors isn't one to overlook: Past performance really may not be indicative of future results.....
3 Big Pharma Stocks Set to Succeed
That disclaimer that the Securities and Exchange Commission requires mutual funds to provide to investors isn't one to overlook: Past performance really may not be indicative of future results.....
3 Big Pharma Stocks Set to Succeed
That disclaimer that the Securities and Exchange Commission requires mutual funds to provide to investors isn't one to overlook: Past performance really may not be indicative of future results.....
If You're in Your 40s, Consider Buying This Stock
If you're a 40-year-old investor, you're probably not planning on retiring for another 20 years or more. While that may be a bit of a downer for those looking forward to the freedom that....
If You're in Your 40s, Consider Buying This Stock
If you're a 40-year-old investor, you're probably not planning on retiring for another 20 years or more. While that may be a bit of a downer for those looking forward to the freedom that....